Designing a multi-epitope vaccine candidate against human rhinovirus C utilizing immunoinformatics approach

Human rhinovirus C (HRV-C) is a significant contributor to respiratory tract infections in children and is implicated in asthma exacerbations across all age groups. Despite its impact, there is currently no licensed vaccine available for HRV-C. Here, we present a novel approach to address this gap b...

Full description

Saved in:
Bibliographic Details
Main Authors: Tajul Islam Mamun, Md. Ahad Ali, Md. Nazmul Hosen, Jillur Rahman, Md. Anwarul Islam, Md. Golam Akib, Kamruz Zaman, Md. Masudur Rahman, Ferdaus Mohd Altaf Hossain, Samir Ibenmoussa, Mohammed Bourhia, Turki M. Dawoud
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1364129/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850085334629482496
author Tajul Islam Mamun
Tajul Islam Mamun
Md. Ahad Ali
Md. Nazmul Hosen
Jillur Rahman
Md. Anwarul Islam
Md. Golam Akib
Kamruz Zaman
Md. Masudur Rahman
Md. Masudur Rahman
Ferdaus Mohd Altaf Hossain
Ferdaus Mohd Altaf Hossain
Samir Ibenmoussa
Mohammed Bourhia
Turki M. Dawoud
author_facet Tajul Islam Mamun
Tajul Islam Mamun
Md. Ahad Ali
Md. Nazmul Hosen
Jillur Rahman
Md. Anwarul Islam
Md. Golam Akib
Kamruz Zaman
Md. Masudur Rahman
Md. Masudur Rahman
Ferdaus Mohd Altaf Hossain
Ferdaus Mohd Altaf Hossain
Samir Ibenmoussa
Mohammed Bourhia
Turki M. Dawoud
author_sort Tajul Islam Mamun
collection DOAJ
description Human rhinovirus C (HRV-C) is a significant contributor to respiratory tract infections in children and is implicated in asthma exacerbations across all age groups. Despite its impact, there is currently no licensed vaccine available for HRV-C. Here, we present a novel approach to address this gap by employing immunoinformatics techniques for the design of a multi-epitope-based vaccine against HRV-C. The sequences of the chosen structural proteins VP1 and VP2, along with the non-structural protein 2C of HRV-C, were downloaded in FASTA format from the NCBI server for further analysis. Through an exhaustive analysis of HRV-C genomic sequences, we identified highly conserved immunogenic regions capable of eliciting a protective immune response. Leveraging advanced immunoinformatics tools, we predicted epitopes for B-cells, Cytotoxic T lymphocytes, and Helper T lymphocytes, ensuring broad coverage across different HRV-C strains. The vaccine candidate was constructed by integrating selected antigens with immunogenic epitopes and adjuvants, employing optimal linkers. Three vaccine constructs were developed, with V2 being the most promising, consisting of 480 amino acids residues. V2 exhibited strong antigenicity, non-allergenicity, and solubility, with a solubility score greater than 0.550, and demonstrated excellent structural stability, with 91.9% of residues in the most favorable regions of the Ramachandran plot. Molecular dynamics and simulation studies revealed a stable Vaccine-TLR8 complex, with a binding energy of -296.15 and consistent RMSD values. Furthermore, in silico cloning and sequence optimization ensured efficient expression in E. coli, with a Codon Adaptation Index of 0.99 and GC content of 54.58%. The minimum free energy of the RNA secondary structure was -494.90 kcal/mol. While our findings suggest the potential effectiveness of the designed vaccine candidate against HRV-C, further in vitro and in vivo investigations are warranted to validate its safety and efficacy.
format Article
id doaj-art-95a664a6ab5c4b2abc261bbd0ebefd51
institution DOAJ
issn 1664-3224
language English
publishDate 2025-01-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj-art-95a664a6ab5c4b2abc261bbd0ebefd512025-08-20T02:43:45ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011510.3389/fimmu.2024.13641291364129Designing a multi-epitope vaccine candidate against human rhinovirus C utilizing immunoinformatics approachTajul Islam Mamun0Tajul Islam Mamun1Md. Ahad Ali2Md. Nazmul Hosen3Jillur Rahman4Md. Anwarul Islam5Md. Golam Akib6Kamruz Zaman7Md. Masudur Rahman8Md. Masudur Rahman9Ferdaus Mohd Altaf Hossain10Ferdaus Mohd Altaf Hossain11Samir Ibenmoussa12Mohammed Bourhia13Turki M. Dawoud14Department of Epidemiology and Public Health, Sylhet Agricultural University, Sylhet, BangladeshFaculty of Veterinary, Animal and Biomedical Sciences, Sylhet Agricultural University, Sylhet, BangladeshDepartment Of Chemistry, University of Rajshahi, Rajshahi, BangladeshDepartment of Pharmacology and Toxicology, Sylhet Agricultural University, Sylhet, BangladeshFaculty of Veterinary, Animal and Biomedical Sciences, Sylhet Agricultural University, Sylhet, BangladeshFaculty of Veterinary, Animal and Biomedical Sciences, Sylhet Agricultural University, Sylhet, BangladeshFaculty of Veterinary, Animal and Biomedical Sciences, Sylhet Agricultural University, Sylhet, BangladeshFaculty of Veterinary, Animal and Biomedical Sciences, Sylhet Agricultural University, Sylhet, BangladeshFaculty of Veterinary, Animal and Biomedical Sciences, Sylhet Agricultural University, Sylhet, BangladeshDepartment of Pathology, Sylhet Agricultural University, Sylhet, BangladeshFaculty of Veterinary, Animal and Biomedical Sciences, Sylhet Agricultural University, Sylhet, BangladeshDepartment of Dairy Science, Sylhet Agricultural University, Sylhet, BangladeshLaboratory of Therapeutic and Organic Chemistry, Faculty of Pharmacy, University of Montpellier, Montpellier, FranceDepartment of Chemistry and Biochemistry, Faculty of Medicine and Pharmacy, Ibn Zohr University, Laayoune, MoroccoDepartment of Botany and Microbiology, College of Science, King Saud University, Riyadh, Saudi ArabiaHuman rhinovirus C (HRV-C) is a significant contributor to respiratory tract infections in children and is implicated in asthma exacerbations across all age groups. Despite its impact, there is currently no licensed vaccine available for HRV-C. Here, we present a novel approach to address this gap by employing immunoinformatics techniques for the design of a multi-epitope-based vaccine against HRV-C. The sequences of the chosen structural proteins VP1 and VP2, along with the non-structural protein 2C of HRV-C, were downloaded in FASTA format from the NCBI server for further analysis. Through an exhaustive analysis of HRV-C genomic sequences, we identified highly conserved immunogenic regions capable of eliciting a protective immune response. Leveraging advanced immunoinformatics tools, we predicted epitopes for B-cells, Cytotoxic T lymphocytes, and Helper T lymphocytes, ensuring broad coverage across different HRV-C strains. The vaccine candidate was constructed by integrating selected antigens with immunogenic epitopes and adjuvants, employing optimal linkers. Three vaccine constructs were developed, with V2 being the most promising, consisting of 480 amino acids residues. V2 exhibited strong antigenicity, non-allergenicity, and solubility, with a solubility score greater than 0.550, and demonstrated excellent structural stability, with 91.9% of residues in the most favorable regions of the Ramachandran plot. Molecular dynamics and simulation studies revealed a stable Vaccine-TLR8 complex, with a binding energy of -296.15 and consistent RMSD values. Furthermore, in silico cloning and sequence optimization ensured efficient expression in E. coli, with a Codon Adaptation Index of 0.99 and GC content of 54.58%. The minimum free energy of the RNA secondary structure was -494.90 kcal/mol. While our findings suggest the potential effectiveness of the designed vaccine candidate against HRV-C, further in vitro and in vivo investigations are warranted to validate its safety and efficacy.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1364129/fullhuman rhinovirus Cmulti-epitope vaccineepitope predictionreverse vaccinologyimmunoinformatics
spellingShingle Tajul Islam Mamun
Tajul Islam Mamun
Md. Ahad Ali
Md. Nazmul Hosen
Jillur Rahman
Md. Anwarul Islam
Md. Golam Akib
Kamruz Zaman
Md. Masudur Rahman
Md. Masudur Rahman
Ferdaus Mohd Altaf Hossain
Ferdaus Mohd Altaf Hossain
Samir Ibenmoussa
Mohammed Bourhia
Turki M. Dawoud
Designing a multi-epitope vaccine candidate against human rhinovirus C utilizing immunoinformatics approach
Frontiers in Immunology
human rhinovirus C
multi-epitope vaccine
epitope prediction
reverse vaccinology
immunoinformatics
title Designing a multi-epitope vaccine candidate against human rhinovirus C utilizing immunoinformatics approach
title_full Designing a multi-epitope vaccine candidate against human rhinovirus C utilizing immunoinformatics approach
title_fullStr Designing a multi-epitope vaccine candidate against human rhinovirus C utilizing immunoinformatics approach
title_full_unstemmed Designing a multi-epitope vaccine candidate against human rhinovirus C utilizing immunoinformatics approach
title_short Designing a multi-epitope vaccine candidate against human rhinovirus C utilizing immunoinformatics approach
title_sort designing a multi epitope vaccine candidate against human rhinovirus c utilizing immunoinformatics approach
topic human rhinovirus C
multi-epitope vaccine
epitope prediction
reverse vaccinology
immunoinformatics
url https://www.frontiersin.org/articles/10.3389/fimmu.2024.1364129/full
work_keys_str_mv AT tajulislammamun designingamultiepitopevaccinecandidateagainsthumanrhinoviruscutilizingimmunoinformaticsapproach
AT tajulislammamun designingamultiepitopevaccinecandidateagainsthumanrhinoviruscutilizingimmunoinformaticsapproach
AT mdahadali designingamultiepitopevaccinecandidateagainsthumanrhinoviruscutilizingimmunoinformaticsapproach
AT mdnazmulhosen designingamultiepitopevaccinecandidateagainsthumanrhinoviruscutilizingimmunoinformaticsapproach
AT jillurrahman designingamultiepitopevaccinecandidateagainsthumanrhinoviruscutilizingimmunoinformaticsapproach
AT mdanwarulislam designingamultiepitopevaccinecandidateagainsthumanrhinoviruscutilizingimmunoinformaticsapproach
AT mdgolamakib designingamultiepitopevaccinecandidateagainsthumanrhinoviruscutilizingimmunoinformaticsapproach
AT kamruzzaman designingamultiepitopevaccinecandidateagainsthumanrhinoviruscutilizingimmunoinformaticsapproach
AT mdmasudurrahman designingamultiepitopevaccinecandidateagainsthumanrhinoviruscutilizingimmunoinformaticsapproach
AT mdmasudurrahman designingamultiepitopevaccinecandidateagainsthumanrhinoviruscutilizingimmunoinformaticsapproach
AT ferdausmohdaltafhossain designingamultiepitopevaccinecandidateagainsthumanrhinoviruscutilizingimmunoinformaticsapproach
AT ferdausmohdaltafhossain designingamultiepitopevaccinecandidateagainsthumanrhinoviruscutilizingimmunoinformaticsapproach
AT samiribenmoussa designingamultiepitopevaccinecandidateagainsthumanrhinoviruscutilizingimmunoinformaticsapproach
AT mohammedbourhia designingamultiepitopevaccinecandidateagainsthumanrhinoviruscutilizingimmunoinformaticsapproach
AT turkimdawoud designingamultiepitopevaccinecandidateagainsthumanrhinoviruscutilizingimmunoinformaticsapproach